Skip to main content

PAN EBOLA VACCINE INNOVATIVE APPROACH – Sofia ref.: 116088

Objective

Ebola virus (EBOV), a member of Filoviridae family of viruses, is one of the most dangerous microorganisms in the world, causing severe hemorrhagic fevers in humans and non-human primates with high case fatality. Since its discovery in 1976, five different Ebola virus species have been isolated and over 20 sporadic EBOV outbreaks have occurred, mostly confined to rural areas in East and Central Africa. Hence the disease did not attract much global attention. However, the 2014 Ebola outbreak in West Africa, caused by Ebola Zaire strain, gained widespread attention as it took a different pattern and has reached historic proportions, characterized by a rapid and larger spread beyond Africa, and a greater magnitude than all the other outbreaks combined, underscoring its serious threat to the public health. No vaccines or antiviral drugs currently approved for prevention or treatment of Ebola infections in humans. However, the severity of the recent Ebola outbreak and the potential risk of global spread, has spurred research for the rapid development of safe and effective preventive Ebola vaccine. Such a vaccine, that can rapidly induce strong and long-lasting protective immune responses against all main Ebola strains and that can be readily produce and deployed in the field, is needed to protect people in endemic regions in an event of an outbreak but also to protect healthcare workers caring for Ebola patients, who are at the highest risk of infection even before an outbreak can be identified.

A number of EBOV vaccine candidates are under development and some have been shown to induce protective immune responses against lethal Ebola virus infection in different animal models, including non-human primates. In response to the recent Ebola outbreak, three main promising monovalent vector-based vaccines are being investigated in human clinical trials, demonstrating their safety and immunogenicity and the potential efficacy of a Vesicular Stomatitis Virus-based vaccine

Call for proposal

H2020-JTI-IMI2-2015-08-single-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
Address
3 Avenue Victoria
75000 Paris
France
Activity type
Research Organisations
EU contribution
€ 1 297 406

Participants (13)

HEINRICH-PETTE INSTITUT LEIBNIZ INSTITUT FUER EXPERIMENTELLE VIROLOGIE
Germany
EU contribution
€ 81 250
Address
Martinistrasse 52
20251 Hamburg
Activity type
Research Organisations
EXCELLGENE SA
Switzerland
EU contribution
€ 0
Address
Route De L'ile-au-bois 1A
1870 Monthey
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
France
EU contribution
€ 1 040 108
Address
Rue Leblanc 25
75015 Paris 15
Activity type
Research Organisations
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
Switzerland
EU contribution
€ 0
Address
Rue Du Bugnon 21
1011 Lausanne
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France
EU contribution
€ 533 332
Address
Rue Michel Ange 3
75794 Paris
Activity type
Other
OLIGOVAX
France
EU contribution
€ 863 000
Address
102 Avenue Des Champs-elysees
75008 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN
Germany
EU contribution
€ 182 500
Address
Bernhard Nocht Strasse 74
20359 Hamburg
Activity type
Research Organisations
CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE
France
EU contribution
€ 603 125
Address
Avenue Oscar Lambret 2
59037 Lille
Activity type
Higher or Secondary Education Establishments
VAXEAL RESEARCH
France
EU contribution
€ 0
Address
4 Rue Pierre Fontaine, Pepinere Genopole Enterpris
91058 Evry
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITE D'ABOMEY-CALAVI
Benin
EU contribution
€ 566 312
Address
Campus Universitaires D Abomey
01 Abomey Calavi
Activity type
Higher or Secondary Education Establishments
IFAKARA HEALTH INSTITUTE TRUST
Tanzania
EU contribution
€ 502 000
Address
Kiko Avenue Off Old Bagamoyo Road Plot 463
Dar Es Salaam
Activity type
Research Organisations
ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO
Italy
EU contribution
€ 273 650
Address
Via Portuense, 292
00149 Roma
Activity type
Research Organisations
ISTITUTO SUPERIORE DI SANITA
Italy
EU contribution
€ 246 887
Address
Viale Regina Elena 299
00161 Roma
Activity type
Research Organisations